US · GUTS
Fractyl Health, Inc. Common Stock
- Sector
- Healthcare · Biotechnology
- Headquarters
- Lexington, MA 02421
- Website
- fractyl.com
Price · as of 2024-12-31
$0.70
Market cap 33.88M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $20.54 | +2,837.22% |
| Intrinsic Value(DCF) | $0.56 | -19.92% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $20.98 | +2,899.57% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $8.33 | ||||
| 2024 | $1.41 | $20.54 | $0.00 | $0.00 | $20.98 |
AI valuation
Our deep-learning model estimates Fractyl Health, Inc. Common Stock's (GUTS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $20.54
- Current price
- $0.70
- AI upside
- +2,837.22%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.56
-19.92% upside
Graham-Dodd
—
— upside
Graham Formula
$20.98
+2,899.57% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GUTS | Fractyl Health, Inc. Comm… | $0.70 | 33.88M | +2,837% | -20% | — | +2,900% | -0.89 | 2.16 | 660.15 | -0.61 | — | 2.16 | 46.24% | -100570.97% | -73864.52% | 46.32% | -484.68% | -74.55% | 2.20 | — | 3.63 | 3.41 | 0.05 | -1818.00% | -2250.00% | 5582.00% | -109.60% | -3.31 | -348.68% | 0.00% | 0.00% | 562.21% | -0.60 | -0.84 | 606.77 | -7.20 |
| ADVM | Adverum Biotechnologies, … | $4.36 | 96.26M | +263% | -58% | — | +9,149% | -0.69 | 1.28 | 90.60 | -0.44 | -0.30 | 1.28 | -265.30% | -15315.90% | -13092.70% | -169.83% | -313.49% | -74.21% | 1.30 | — | 5.73 | 5.49 | -0.24 | 22772.00% | -7222.00% | 124.00% | -102.48% | -4.04 | -190.05% | 0.00% | 0.00% | 0.00% | -0.37 | -0.61 | 56.62 | -9.89 |
| ALXO | ALX Oncology Holdings Inc… | $2.11 | 114.42M | — | — | — | — | -0.41 | 0.49 | — | 0.42 | — | 0.49 | 0.00% | — | — | -88.91% | -1054.84% | -69.10% | 0.15 | -82.40 | 7.26 | 6.95 | 0.00 | -3102.00% | — | -705.00% | -221.24% | -6.59 | -905.96% | 0.00% | 0.00% | 0.00% | 0.39 | 0.45 | — | -7.15 |
| ARTV | Artiva Biotherapeutics, I… | $5.82 | 142.85M | +335% | -18% | — | +3,479% | -2.00 | 0.70 | 520.26 | 0.62 | -0.59 | 0.70 | 100.00% | -26805.58% | -23303.98% | -530.93% | 65.16% | -41.55% | 0.08 | — | 15.39 | 15.15 | 0.40 | 33697.00% | -9925.00% | 984.00% | -42.63% | -4.49 | 53.92% | 0.00% | 0.00% | 3.20% | 0.60 | 0.73 | -161.31 | 1.72 |
| ATYR | aTyr Pharma, Inc. | $0.96 | 94.05M | +2,378% | +42% | — | +2,039% | -3.94 | 3.61 | 1074.42 | -2.92 | — | 3.61 | 100.00% | -28899.57% | -27243.83% | -79.69% | -723.88% | -58.88% | 0.19 | — | 5.48 | 4.93 | -0.03 | -851.00% | -3343.00% | 8481.00% | -27.40% | -4.62 | -737.41% | 0.00% | 0.00% | 0.00% | -2.85 | -2.80 | 824.03 | -3.56 |
| BMEA | Biomea Fusion, Inc. | $1.37 | 81.51M | — | — | — | — | -0.71 | 1.90 | — | -0.34 | -6.23 | 1.90 | 0.00% | — | — | -125.38% | -6089.18% | -98.92% | 0.17 | — | 3.15 | 2.69 | 0.35 | 1134.00% | — | 2030.00% | -122.90% | -5.53 | -5082.67% | 0.00% | 0.00% | 0.00% | -0.34 | -0.40 | — | -9.96 |
| DTIL | Precision BioSciences, In… | $4.20 | 55.67M | +1,686% | -46% | +221% | +1,082% | 4.94 | 0.63 | 0.52 | -1.54 | — | 0.63 | 100.00% | -38.08% | 10.43% | 19.05% | 78.77% | 4.84% | 0.53 | -14.68 | 6.34 | 5.88 | -4.13 | -10652.00% | 4098.00% | -3206.00% | -165.83% | -3.90 | 176.73% | 0.00% | 0.00% | 0.00% | 0.80 | 0.36 | -0.30 | -4.11 |
| MGX | Metagenomi, Inc. Common S… | $1.52 | 57.07M | +1,047% | +86% | — | — | -0.99 | 0.33 | 1.48 | 1.50 | -6.69 | 0.33 | 100.00% | -170.00% | -149.26% | -34.69% | -676.50% | -22.64% | 0.19 | — | 6.91 | 6.69 | -0.22 | 1484.00% | 1684.00% | 1083.00% | -144.84% | -2.92 | -913.98% | 0.00% | 0.00% | 0.00% | 1.41 | 1.11 | -2.39 | -0.37 |
| QNCX | Quince Therapeutics, Inc. | $0.13 | 7M | — | — | — | — | -1.15 | 2.17 | — | -1.09 | -2.05 | -2.18 | 0.00% | — | — | -98.63% | -409.00% | -38.57% | 0.49 | — | 6.05 | 5.72 | -0.24 | 5595.00% | — | 7430.00% | -49.23% | -4.38 | -229.62% | 0.00% | 0.00% | 0.00% | -0.69 | -1.22 | — | -5.41 |
| RPTX | Repare Therapeutics Inc. | $2.65 | 114.24M | +786% | -68% | — | — | -0.59 | 0.33 | 0.94 | 1.12 | — | 0.33 | 74.98% | -174.88% | -158.37% | -46.63% | 2379.11% | -39.35% | 0.01 | — | 6.77 | 6.53 | 0.92 | -1031.00% | 458.00% | -4078.00% | -152.11% | -3.02 | 1944.67% | 0.00% | 0.00% | 0.00% | 1.08 | 1.32 | -1.88 | -2.58 |
| STRO | Sutro Biopharma, Inc. | $20.47 | 174.27M | -71% | -71% | — | +6,969% | -0.51 | 2.58 | 1.86 | 0.99 | -0.76 | 2.58 | 88.37% | -384.34% | -366.62% | -234.19% | 108.03% | -53.02% | 0.52 | -7.67 | 2.60 | 2.47 | 0.93 | 6629.00% | -5964.00% | 6789.00% | -168.89% | -1.45 | 88.18% | 0.00% | 0.00% | 114.12% | 0.75 | 0.92 | -2.88 | -3.86 |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
- CEO
- Harith Rajagopalan
- Employees
- 107
- Beta
- 1.63
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.56 ÷ $0.70) − 1 = -19.92% (DCF, example).